首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4829722篇
  免费   381520篇
  国内免费   19898篇
耳鼻咽喉   67630篇
儿科学   151121篇
妇产科学   126403篇
基础医学   727209篇
口腔科学   134270篇
临床医学   445398篇
内科学   877873篇
皮肤病学   115987篇
神经病学   402895篇
特种医学   187788篇
外国民族医学   869篇
外科学   730611篇
综合类   141615篇
现状与发展   44篇
一般理论   2740篇
预防医学   392824篇
眼科学   114790篇
药学   348166篇
  63篇
中国医学   16251篇
肿瘤学   246593篇
  2021年   59906篇
  2020年   38675篇
  2019年   61294篇
  2018年   77885篇
  2017年   59830篇
  2016年   65909篇
  2015年   79454篇
  2014年   114507篇
  2013年   179747篇
  2012年   139618篇
  2011年   146613篇
  2010年   132199篇
  2009年   132170篇
  2008年   131043篇
  2007年   139494篇
  2006年   147496篇
  2005年   141463篇
  2004年   141344篇
  2003年   131043篇
  2002年   120088篇
  2001年   192690篇
  2000年   188983篇
  1999年   171104篇
  1998年   75330篇
  1997年   70214篇
  1996年   68105篇
  1995年   63420篇
  1994年   57299篇
  1993年   52970篇
  1992年   124325篇
  1991年   118573篇
  1990年   114333篇
  1989年   111189篇
  1988年   102318篇
  1987年   100312篇
  1986年   94417篇
  1985年   92078篇
  1984年   74799篇
  1983年   66020篇
  1982年   50269篇
  1981年   46484篇
  1980年   43488篇
  1979年   64385篇
  1978年   50443篇
  1977年   44975篇
  1976年   41244篇
  1975年   41972篇
  1974年   46220篇
  1973年   44039篇
  1972年   41346篇
排序方式: 共有10000条查询结果,搜索用时 750 毫秒
931.
Treatment decisions in patients with metastatic bone disease rely on accurate survival estimation. We developed the original PATHFx models using expensive, proprietary software and now seek to provide a more cost-effective solution. Using open-source machine learning software to create PATHFx version 2.0, we asked whether PATHFx 2.0 could be created using open-source methods and externally validated in two unique patient populations. The training set of a well-characterized, database records of 189 patients and the bnlearn package within R Version 3.5.1 (R Foundation for Statistical Computing), was used to establish a series of Bayesian belief network models designed to predict survival at 1, 3, 6, 12, 18, and 24 months. Each was externally validated in both a Scandinavian (n = 815 patients) and a Japanese (n = 261 patients) data set. Brier scores and receiver operating characteristic curves to assessed discriminatory ability. Decision curve analysis (DCA) evaluated whether models should be used clinically. DCA showed that the model should be used clinically at all time points in the Scandinavian data set. For the 1-month time point, DCA of the Japanese data set suggested to expect better outcomes assuming all patients will survive greater than 1 month. Brier scores for each curve demonstrate that the models are accurate at each time point. Statement of Clinical Significance: we successfully transitioned to PATHFx 2.0 using open-source software and externally validated it in two unique patient populations, which can be used as a cost-effective option to guide surgical decisions in patients with metastatic bone disease.  相似文献   
932.
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc.  相似文献   
933.
934.
935.
936.
In this review we summarize the impact of the various modalities of breast cancer therapy coupled with intrinsic patient factors on incidence of subsequent treatment-induced myelodysplasia and acute myelogenous leukemia (t-MDS/AML). It is clear that risk is increased for patients treated with radiation and chemotherapy at younger ages. Radiation is associated with modest risk, whereas chemotherapy, particularly the combination of an alkylating agent and an anthracycline, carries higher risk and radiation and chemotherapy combined increase the risk markedly. Recently, treatment with granulocyte colony-stimulating factor (G-CSF), but not pegylated G-CSF, has been identified as a factor associated with increased t-MDS/AML risk. Two newly identified associations may link homologous DNA repair gene deficiency and poly (ADP-ribose) polymerase inhibitor treatment to increased t-MDS/AML risk. When predisposing factors, such as young age, are combined with an increasing number of potentially leukemogenic treatments that may not confer large risk singly, the risk of t-MDS/AML appears to increase. Patient and treatment factors combine to form a biological cascade that can trigger a myelodysplastic event. Patients with breast cancer are often exposed to many of these risk factors in the course of their treatment, and triple-negative patients, who are often younger and/or BRCA positive, are often exposed to all of them. It is important going forward to identify effective therapies without these adverse associated effects and choose existing therapies that minimize the risk of t-MDS/AML without sacrificing therapeutic gain.

Implications for Practice

Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.
  相似文献   
937.
目的:建立鼠巨细胞病毒(MCMV)感染C57BL/6小鼠急性肝炎模型并对其感染特点进行分析及鉴定。方法:将24 只C57BL/6小鼠随机分为阴性对照组(n =12)及病毒感染组(n =12),病毒感染组腹腔注射1.0×106 PFU(200 μL)MCMV悬液,阴性对照组注射等体积小鼠胚胎成纤维细胞(MEF)悬液。于感染后第3天和第7天取外周血分离血清检测谷丙转氨酶(ALT)及谷草转氨酶(AST)。同时进行肝组织病毒分离、组织病理学及MCMV IE和M55基因、细胞因子白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)、肿瘤坏死因子α(TNF-α)的检测。结果:病毒感染组肝组织匀浆病毒分离均为阳性,肝炎发生率为100%。在感染后第3天即发生肝炎病理改变,病毒感染组血清ALT及AST较阴性对照组明显升高(P <0.01);病毒感染组肝脏HE染色第3天可见局灶性炎性细胞浸润及肝脏点灶状坏死,持续至第7天,Ishak评分较阴性对照组明显升高(P <0.01);在感染后第3天病毒感染组肝组织内可检测到MCMV IE及M55基因,且在感染后第7天仍可测得IE基因;感染后第3天及第7天病毒感染组炎性细胞因子IL-6、TNF-α及IL-1β mRNA表达水平明显升高(P <0.05)。 结论:成功建立MCMV感染C57BL/6小鼠急性动物肝炎模型,其感染表现主要集中在急性感染前期。  相似文献   
938.
939.
940.
We evaluated RNA stability of Ebola virus in EDTA blood and urine samples collected from infected patients and stored in West Africa’s environmental conditions. In blood, RNA was stable for at least 18 days when initial cycle threshold values were <30, but in urine, RNA degradation occurred more quickly.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号